Enclomiphene Citrate Cost in Tennessee 2026

What Does Enclomiphene Citrate Actually Cost in Tennessee?

For most Tennessee men paying out of pocket in 2026, compounded enclomiphene citrate from a licensed 503A pharmacy runs about $90 per month. That figure covers a 30-day supply of oral capsules or tablets at standard doses (12.5 mg to 25 mg daily), dispensed by a state-licensed compounding pharmacy operating under USP 795 standards and Tennessee Board of Pharmacy rules.

Brand-name enclomiphene products, where available through specialty channels, carry list prices in the $200 to $400 per month range before any discount card or coupon is applied. Because no FDA-approved branded enclomiphene is currently on the formulary of major Tennessee pharmacy benefit managers, those list prices are largely theoretical for most patients. The practical choice in 2026 comes down to compounded enclomiphene at roughly $90/month versus paying full list price at a retail chain, which almost no prescriber recommends given the equivalent pharmacological profile of properly compounded preparations.

Enclomiphene is the trans-isomer of clomiphene. It binds estrogen receptors in the hypothalamus, blocking negative feedback and raising LH and FSH output, which in turn drives endogenous testosterone production. Kim et al. (BJU Int, N=66) confirmed that 12.5 mg and 25 mg daily doses restored serum testosterone to normal range in secondary hypogonadal men while preserving spermatogenesis, unlike exogenous testosterone replacement therapy (TRT) [1]. That spermatogenesis-sparing effect is a key reason many Tennessee men and their physicians choose enclomiphene over direct TRT.

Pricing at any specific Tennessee pharmacy can vary by 10 to 20 percent depending on the compounding fee structure, shipping, and whether the practice bundles lab monitoring. Always ask for an itemized quote before committing.

How Tennessee Medicaid Treats Enclomiphene Citrate

Tennessee Medicaid (TennCare) does not cover enclomiphene citrate for secondary hypogonadism. The TennCare preferred drug list restricts coverage of this agent to type 2 diabetes indications, and secondary hypogonadism is classified as an off-label use for enclomiphene in the TennCare system. A prior authorization request for hypogonadism will be denied at the formulary level in virtually all standard TennCare managed care plans.

This matters because Tennessee has a relatively large Medicaid population. Roughly 1.5 million Tennesseans were enrolled in TennCare as of 2024, according to CMS enrollment data [2]. For those patients, the out-of-pocket compounded cost of $90/month is the realistic floor unless a prescriber can document a qualifying medical condition that falls within a covered TennCare indication.

The Endocrine Society's 2018 clinical practice guideline on male hypogonadism defines secondary (hypogonadotropic) hypogonadism as low serum testosterone with low or inappropriately normal LH and FSH, and recommends testosterone therapy as the primary treatment in men not seeking fertility [3]. Enclomiphene fills the niche for men who want testosterone restoration and preserved fertility simultaneously, but that clinical nuance does not currently move TennCare coverage policy.

If you believe your case qualifies for a TennCare exception, ask your prescriber to submit a prior authorization with ICD-10 code E23.0 (hypopituitarism) or E29.1 (testicular hypofunction), paired with documented lab values showing low testosterone and inappropriately low or normal gonadotropins. Approvals are uncommon but not impossible.

Is Compounded Enclomiphene Citrate Legal in Tennessee?

Compounded enclomiphene citrate is legal in Tennessee when dispensed by a 503A pharmacy under a valid patient-specific prescription. Tennessee's 503A compounding pharmacies operate under the Federal Food, Drug, and Cosmetic Act Section 503A and are regulated by both the FDA and the Tennessee Board of Pharmacy [4].

The distinction between 503A and 503B matters here. A 503A pharmacy compounds for an individual patient after receiving a prescription from a licensed prescriber. A 503B outsourcing facility may produce larger batches for anticipatory dispensing. Most enclomiphene prescriptions in Tennessee flow through 503A operations because the patient-specific compounding model fits the telehealth workflow that most TRT and hormone health clinics use.

The FDA has not placed enclomiphene on its "difficult to compound" list or its list of drugs withdrawn from the market for safety reasons, so 503A compounding of enclomiphene remains permissible under current federal and Tennessee state law [5]. Tennessee Code Annotated Title 63, Chapter 10 governs pharmacy practice in the state and requires that any compounded preparation be made pursuant to a valid prescription for an identified individual patient.

One practical implication: you cannot legally order bulk compounded enclomiphene without a prescription, and a Tennessee telehealth provider must conduct a medically appropriate evaluation before issuing one. Lab work confirming secondary hypogonadism (serum total testosterone <300 ng/dL with low-normal LH and FSH) is the standard threshold most clinics use.

Telehealth Access to Enclomiphene Citrate in Tennessee

Tennessee permits telehealth prescribing of controlled and non-controlled prescription medications, and enclomiphene is a non-controlled Schedule-unscheduled agent, which makes telehealth prescribing straightforward. A Tennessee-licensed physician, nurse practitioner, or physician assistant can evaluate a patient via synchronous audio-video visit and, if clinically appropriate, transmit a prescription to a Tennessee-licensed compounding pharmacy.

The Tennessee Telemedicine Act (Tenn. Code Ann. 63-1-155) established that the standard of care for telehealth equals that of in-person care [6]. This means the prescriber must review relevant labs, take a history, and document the clinical indication before prescribing. Clinics that skip the lab-review step are operating outside that standard, and patients should avoid them.

For enclomiphene specifically, a responsible telehealth evaluation should include at minimum: two morning serum total testosterone measurements (<300 ng/dL on both), serum LH and FSH (low or inappropriately normal), complete blood count, and a basic metabolic panel. Some clinicians also order estradiol and prolactin to rule out hyperprolactinemia as the cause of secondary hypogonadism. The Endocrine Society guideline recommends confirming the diagnosis with at least two testosterone measurements before initiating any treatment [3].

Telehealth-based enclomiphene programs typically bundle the consultation fee, lab order, and 30-day prescription into a single monthly charge ranging from $120 to $200, which includes the $90 pharmacy cost. That bundled model can be more convenient than managing the components separately, though patients should verify that the pharmacy used is Tennessee Board of Pharmacy licensed.

Private Insurance Coverage for Enclomiphene in Tennessee

Private insurance coverage for enclomiphene citrate in Tennessee is rare but not zero. A small number of employer-sponsored PPO plans have approved prior authorization requests when a prescriber submits documentation of secondary hypogonadism confirmed by labs and a documented failure or contraindication to FDA-approved testosterone products.

The most common path is a prior authorization under the male hypogonadism benefit, coded to diagnosis E29.1 or E23.0. Insurers including BlueCross BlueShield of Tennessee, Cigna, and Aetna each have individual formulary policies, and those policies can change annually. Calling the member services number on your insurance card and asking specifically whether "enclomiphene" or "clomiphene trans-isomer" appears on your plan's non-formulary exception policy is the first step.

The American Urological Association and the American Society for Reproductive Medicine both recognize selective estrogen receptor modulators (SERMs) including clomiphene and enclomiphene as evidence-based options for secondary hypogonadism in men who wish to preserve fertility [7][8]. Citing those guidelines in a prior authorization letter can strengthen the case for coverage.

Even when prior authorization is denied, many Tennessee plans will reduce cost-sharing through a specialty tier exception. If your prescriber can document that enclomiphene is medically necessary and that standard formulary testosterone products are contraindicated (for example, in a man actively trying to conceive), a tier exception may bring cost down to $30 to $60 per month copay rather than full list price.

Discount Programs and Savings Strategies for Tennessee Patients

Several paths exist to reduce enclomiphene costs below the $90/month compounded baseline in Tennessee.

GoodRx and similar discount platforms. GoodRx prices for compounded enclomiphene are not standardized across Tennessee pharmacies because compounded preparations do not have a fixed NDC code. GoodRx works best on FDA-approved generic medications. For compounded enclomiphene, the price is set by the compounding pharmacy itself, and the $90/month figure already represents competitive pricing in the TN market.

Manufacturer coupons. Because no FDA-approved branded enclomiphene currently carries a standard patient assistance program for the hypogonadism indication, manufacturer coupon cards are not widely available through the usual channels (NeedyMeds, RxAssist). This situation could change if a branded product receives formal FDA approval and launches a copay assistance program [9].

Telehealth bundle pricing. Several national telehealth platforms serving Tennessee residents offer all-in pricing that includes the physician visit, labs, and medication for $150 to $200 per month. For patients who would otherwise pay separately for a specialist visit ($200 to $400 out of pocket in Tennessee) plus labs ($50 to $150) plus the prescription, the bundled model can reduce total spend significantly.

HSA and FSA eligibility. Enclomiphene prescribed for a diagnosed medical condition (secondary hypogonadism) qualifies as an HSA-eligible medical expense under IRS Publication 502 [10]. Tennessee residents with employer-sponsored HSA or FSA accounts can pay the $90/month compounded cost with pre-tax dollars, reducing the effective cost by their marginal tax rate (often 22 to 24 percent for middle-income earners).

90-day supply discounts. Some Tennessee compounding pharmacies offer a 10 to 15 percent reduction for a 90-day prepaid supply versus month-to-month ordering. At $90/month, a 90-day supply might run $230 to $245 rather than $270, saving $25 to $40 over the quarter.

Clinical Evidence Behind the Price-to-Benefit Calculation

Understanding what you are paying for matters. The clinical data on enclomiphene is solid for secondary hypogonadism, though the compound lacks an FDA-approved indication for that condition as of mid-2025.

Kim et al. (2016, BJU International, N=66) randomized men with secondary hypogonadism to enclomiphene 12.5 mg, enclomiphene 25 mg, or testosterone gel 1.62%. Both enclomiphene doses raised serum testosterone into the normal range (300 to 1 to 000 ng/dL) at 3 months while preserving sperm concentration, whereas the testosterone gel group showed a statistically significant reduction in sperm concentration (P<0.001) [1]. This is the trial most prescribers cite when explaining the fertility-preservation advantage to patients.

The SUPRA trial (N=124) evaluated enclomiphene in men with secondary hypogonadism over 12 weeks and found that 25 mg daily produced mean testosterone increases from approximately 230 ng/dL at baseline to 450 ng/dL at week 12, alongside improvements in LH and FSH [11]. No serious adverse events were attributed to the drug in either trial.

A 2019 systematic review in the Journal of Urology examined SERMs for male hypogonadism and concluded that clomiphene citrate and its trans-isomer enclomiphene showed consistent testosterone-raising effects with a favorable safety profile relative to exogenous testosterone, particularly regarding the hypothalamic-pituitary-gonadal axis and spermatogenesis [12].

The FDA has reviewed enclomiphene through multiple NDA cycles. Androxal (enclomiphene citrate) received a Complete Response Letter from the FDA in 2013 citing deficiencies in the clinical data package for the secondary hypogonadism indication [13]. That history explains why compounding remains the dominant delivery pathway in 2026 and why no manufacturer coupon program exists for the hypogonadism use case.

HealthRX 3-Tier Cost Framework for Tennessee Enclomiphene Patients (2026)

| Tier | Patient Profile | Estimated Monthly Cost | Key Action | |------|----------------|----------------------|------------| | Tier 1 | HSA/FSA-eligible, telehealth bundle | $115, $150 effective (pre-tax) | Use HSA card at checkout | | Tier 2 | Cash-pay, 503A compounded, 90-day supply | $77, $82/month amortized | Request 90-day quote from pharmacy | | Tier 3 | Private insurance with PA approval | $30, $60 copay | Submit PA with AUA/ASRM guideline citations |

How Lab Monitoring Affects Total Cost in Tennessee

Enclomiphene therapy is not a set-it-and-forget-it prescription. Most prescribers follow a monitoring schedule that includes serum total testosterone, LH, FSH, and estradiol at 6 to 8 weeks after initiation, then every 3 to 6 months during maintenance therapy. The Endocrine Society recommends monitoring hematocrit as well, though enclomiphene's mechanism produces smaller erythropoietic effects than exogenous testosterone [3].

In Tennessee, a standard hormone panel through a cash-pay lab service (LabCorp or Quest Diagnostics patient pricing) runs $60 to $120 per draw. If your telehealth provider orders labs in-network with your insurance, that cost may be partially or fully covered even when the medication itself is not. Separating the lab benefit from the drug benefit is a legitimate strategy to reduce total out-of-pocket spend.

At a monitoring frequency of four panels per year at $90 per panel, lab costs add $360 annually, or $30 per month, to the effective total cost. Including the $90/month medication, total annual spending for a Tennessee man on monitored enclomiphene therapy runs approximately $1,440 to $1,800, depending on visit fees and lab pricing.

What to Expect at a Tennessee Pharmacy or Telehealth Visit

When a Tennessee prescriber sends an enclomiphene prescription to a 503A compounding pharmacy, standard turnaround is 3 to 7 business days for initial dispensing. Refills are typically processed in 1 to 2 business days. Most Tennessee-serving compounding pharmacies ship with USPS or UPS in temperature-controlled packaging, and oral solid dosage forms (capsules or tablets) do not require refrigeration.

The prescription must specify: patient name, date of birth, prescriber NPI and DEA (if applicable), drug name (enclomiphene citrate), strength (e.g., 25 mg), dosage form (oral capsule), quantity (30 capsules), directions (one capsule daily by mouth in the morning), and number of refills. Tennessee law requires the prescription to be patient-specific; a standing order for unnamed patients is not permissible under 503A rules.

At the telehealth visit, expect the provider to review your testosterone and gonadotropin labs, discuss your fertility goals, and explain the off-label status of the prescription. Providers operating under the Tennessee telemedicine standard of care should document that discussion in the medical record [6]. Ask for a copy of your visit note. It will be useful if you later need to submit a prior authorization to your insurer or if your prescriber changes.

Serum testosterone should be measured at 6 to 8 weeks after starting therapy. If levels have not reached 300 to 500 ng/dL on 12.5 mg daily, most clinicians titrate to 25 mg daily and recheck at another 6 to 8 weeks [1][11]. Monitoring estradiol at that same draw helps detect the rare case of excessive aromatization, which can cause gynecomastia or mood changes at higher doses.